UNSPSC 51314322: Brompheniramine/guaifenesin/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314322 Brompheniramine/guaifenesin/phenylephrine/phenylpropanolamine is a Commodity code that nominally describes a specific combination decongestant and antihistamine pharmaceutical product, but recent state and local opportunities reveal significant misalignment between the code's name and actual procurement activity. The opportunities tagged under this code address broader pharmaceutical supply chains: Seminole County, Florida is procuring naloxone and drug deactivation systems; the Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is sourcing generic multi-source pharmaceuticals and OTC products across participating state and local facilities. The actual buying pattern spans emergency-response pharmaceuticals, pharmacy benefit management infrastructure, and commoditized generic drug supply, not the specific branded or generic formulation the code nominally describes. State and local issuing bodies using this code include county public-health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Activity is distributed across the South, Midwest, and South-central regions: Seminole County in Florida issued an Invitation for Bid (IFB 60459723LAS) posted June 30, 2026 with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; MMCAP, administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) on January 20, 2026 with responses due March 26, 2026 for generic pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating jurisdictions; and the Texas Health and Human Services Commission issued a Request for Information (HHS0017013) on April 3, 2026 to assess vendor capacity for direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and the actual procurement activity suggests this code may be misapplied by issuing bodies, or the recent opportunities have been incorrectly tagged; business development professionals should verify product specifications against actual RFP language rather than rely on the UNSPSC name alone.